SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical
company focused on discovering, acquiring, developing and
commercializing therapeutics in the disease areas of immunology,
inflammation and oncology, today announced the closing of its previously
announced initial public offering of 19,837,500 shares of its common
stock, which includes the exercise in full by the underwriters of their
option to purchase 2,587,500 additional shares, at a price to the public
of $16.00 per share. Including the option exercise, the aggregate gross
proceeds to Gossamer Bio from the offering, before deducting the
underwriting discounts and commissions and other offering expenses,
were $317.4 million. Gossamer Bio’s common stock is listed on the Nasdaq
Global Select Market under the ticker symbol “GOSS.”
BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI acted as
joint book-running managers for the offering.
Registration statements relating to these securities have been filed
with the Securities and Exchange Commission and became effective
on February 7, 2019. A prospectus relating to and describing the terms
of the offering has been filed with the SEC and is available on the
SEC’s website at www.sec.gov.
The offering was made only by means of a prospectus. Copies of the final
prospectus related to this offering can be obtained from BofA Merrill
Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte,
NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@baml.com;
or from SVB Leerink, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525,
ext. 6132, or by email at syndicate@svbleerink.com;
or from Barclays, c/o Broadridge Financial Solutions, Attn: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone
at (888) 603-5847, or by email at barclaysprospectus@broadridge.com;
or from Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055, or by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there be any
offer or sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on
discovering, acquiring, developing and commercializing therapeutics in
the disease areas of immunology, inflammation and oncology. Its goal is
to be an industry leader in each of these therapeutic areas and to
enhance and extend the lives of patients suffering from such diseases.
Contacts
Gossamer Bio:
For Investors:
Argot Partners
Kimberly
Minarovich
Tel 212.600.1902
kimberly@argotpartners.com
For
Media:
Argot Partners
David Rosen
Tel 212.600.1902
david.rosen@argotpartners.com
